CLAIM AMENDMENTS

In the Claims:

Please cancel claims 3-17. Please enter new claims 20-48 and amend claim 1 as follows:

---

1. (currently amended) ~~A process for delivering a polymer to a cell, in vivo, comprising:~~
   ~~a) assisting delivery to the cell by electrostatically associating a chelator with the polymer;~~
   ~~b) delivering the polymer to the inside of the cell; and,~~
   ~~c) expressing the polymer.~~

   A process for delivering a polynucleotide to a cell comprising:

   a) forming a complex consisting of a polynucleotide and a chelator, wherein electrostatic interaction of the chelator with one or more components of the complex requires the presence of a metal ion coordinated by the chelator; and,

   b) delivering the complex to the cell.

2-17. (canceled)

18. (withdrawn)

19. (withdrawn)

C1

20. (new) The process of claim 1 wherein the chelator consists of a polychelator.

21. (new) The process of claim 1 wherein the chelator consists of a crown ether.

22. (new) The process of claim 20 wherein a plurality of chelators is covalently linked to a polymer.

23. (new) The process of claim 20 wherein the polychelator is formed by covalently polymerizing chelator monomers.

24. (new) The process of claim 20 wherein the polychelator condenses the polynucleotide.

25. (new) The process of claim 24 wherein condensation of the polynucleotide requires the presence of cations.

26. (new) The process of claim 1 wherein the chelator is covalently linked to a compound selected from the list consisting of: a hydrophobic group, a cell receptor signal, a releasing signal, and a steric stabilizer.

27. (new) The process of claim 1 wherein the polynucleotide is expressible.

DEO 6-1-04

28. (new) The process of claim ~~27~~ 27 wherein the polynucleotide expresses a therapeutic gene.